Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Chlorpheniramine Polistirex · Chlor-Trimeton, Efidac 24 Chlorpheniramine Maleate

Small molecule · Antagonist of histamine H1 receptor (HRH1) · developed by Schering

Approved FDA, Jul 1949
1 Registered trials

What is Chlorpheniramine Polistirex?

Chlorpheniramine polistirex is a complex of the alkylamine antihistamine chlorpheniramine with a sulfonated styrene-divinylbenzene copolymer. It competitively blocks the H1 receptor, preventing histamine-mediated vasodilation and edema of respiratory mucosa, and displays anticholinergic and mild sedative effects. It is used for allergic conditions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Chlor-Trimeton, Efidac 24 Chlorpheniramine Maleate, chlorpheniramine
Drug type
Small molecule
Targets
histamine H1 receptor (HRH1)
Mechanism
Antagonist of histamine H1 receptor (HRH1)
Pathways
vasodilation inhibition
Therapy area
Gastroenterology, Infectious disease
Developer
Schering
In trials of
ARWR
FDA status
Approved as Chlor-Trimeton, Efidac 24 Chlorpheniramine Maleate (July 13, 1949), NDA006921

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02065336 Phase 2 Hepatitis B, Chronic Terminated ARWR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatitis B, Chronic

Other drugs acting on HRH1

Cetirizine FDA approved

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.